Background 

Bladder cancer can sometimes be treated with a type of medicine called immunotherapy, which helps the body’s own immune system fight cancer. However, these treatments do not work well for everyone, and many patients still see their cancer return. One immune system protein, called Interleukin-2 (IL2), has shown promise as a powerful cancer-fighting therapy. Unfortunately, natural IL2 can cause serious side effects and can sometimes activate the wrong types of immune cells, which actually weaken the body’s ability to fight cancer. In addition, IL2 usually doesn’t create long-lasting immune protection to stop the cancer from coming back. To fix these problems, the research team has redesigned IL2 in the lab so that it better activates the body’s cancer-fighting cells while avoiding harmful effects. In studies with mice, these engineered IL2 drugs have already been shown to shrink bladder tumors and work even better when used together with existing immunotherapies. 

What the Study Proposes to Address 

This study aims to improve and refine these newly engineered IL2 drugs so they can eventually be tested in humans with bladder cancer. The researchers will focus on making the drugs target tumors more precisely and help the immune system “remember” how to attack bladder cancer cells in the future. The team includes scientists and doctors who specialize in immunotherapy, drug design, and bladder cancer treatment. They will test the current versions of the IL2 drugs to see how well they produce cancer-killing immune cells and long-lasting memory cells. They will also study how the cancer itself may block immune attacks, so they can understand why certain treatments work or fail. These experiments will use special mouse models of bladder cancer that allow scientists to closely track tumor growth, immune responses, and side effects. 

Why This Research is Important 

This project could lead to a major breakthrough in bladder cancer treatment by creating safer, more effective immune-based therapies. If successful, the new IL2 drugs could give doctors better tools to help patients whose cancers don’t respond to current treatments. In the short term, this research will help identify which versions of the drug and which combinations with existing therapies work best. In the long term, the goal is to move these discoveries from the laboratory to clinical trials in people with bladder cancer, with the hope of developing new, potentially curative treatments that strengthen the immune system’s ability to fight cancer—and keep it from coming back. 

None Reported as of August 2025

None Reported as of August 2025

Jamie Spangler, PhD; Johns Hopkins University